Glaxosmithkline plc (GSK) expanded the terms and sweetened the economics of its strategic collaboration and licensing agreement with Adaptimmune Therapeutics plc for a T-cell receptor (TCR) engineered cancer immunotherapy program initially targeting NY-ESO-1.